Niagen Bioscience Execs to Present at ROTH Conference, Highlight Healthy Aging Tech — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience CEO Rob Fried and CFO Ozan Pamir to attend 38th Annual ROTH Conference March 22–24, 2026.
Fried to participate in 'Technologies Advancing Healthy Aging' panel on March 23.
Company to hold one-on-one investor meetings during the event.
Tru Niagen remains the top NAD+ boosting supplement in the U.S. by revenue (2025).

The big picture

Niagen Bioscience's participation in the ROTH Conference underscores the growing institutional interest in healthy aging technologies. As NAD+ science gains traction, the company's ability to articulate its competitive advantages—particularly its patent-protected NR formulations and clinical validation—will be critical. With Tru Niagen maintaining its market-leading position, the focus now shifts to whether Niagen Bioscience can translate this momentum into broader pharmaceutical applications.

What we're watching

Market Positioning: Whether Niagen Bioscience can leverage this platform to strengthen its leadership in the NAD+ boosting market.
Investor Sentiment: How the one-on-one investor meetings may impact near-term stock performance.
Regulatory Compliance: The pace at which Niagen Plus expands its FDA-registered 503B outsourcing facilities.